MOLN Molecular Partners Ltd: Enterprise Value to EBITDA Ratio

Brandmark of Molecular Partners (MOLN)

The EV/EBITDA chart for Molecular Partners AG (MOLN), where the metric stands at 0.00, highlights the impact of strict FDA oversight and DARPin patent protection on its market position. Molecular Partners AG (MOLN) strives for leadership in targeted therapy by developing stable protein-based anti-tumor drugs. Meanwhile, production resources are operating optimally, and the modernization of synthesis lines ensures the reliability of all technological cycles.

MOLN Molecular Partners AG: Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/12/2026

Metric breakdowns and analytics for Molecular Partners Ltd (MOLN)

- stock price and consensus target price:
Stock Quotes Molecular Partners|MOLN - Average Forecast Price
- company stock capitalization data:
Market Valuation Molecular Partners|MOLN - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share Molecular Partners|MOLN - Net Asset Value|Market Value to Book Value Ratio molecularpartners.com|MOLN - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Molecular Partners AG|MOLN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Molecular Partners AG|MOLN - Company Cumulative Indebtedness|Debts to Book Capitalization Molecular Partners|MOLN - Long-Term Liabilities|Company Short-Term Debt Molecular Partners|Quick Liquidity molecularpartners.com
- business earnings and investment ratios data:
MOLN - Final Profit|Expected Profit Molecular Partners AG|MOLN - Price to Earnings Ratio|Future Price to Earnings Molecular Partners|MOLN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Molecular Partners|MOLN - Operating profit before deduction of amortization|Earnings per share for the last twelve months Molecular Partners|MOLN - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months molecularpartners.com|MOLN - Earnings per share growth in current year|Earnings growth forecast for next year Molecular Partners AG
General company analysis:Molecular Partners MOLN
Product sample of molecularpartners.com

The EV/EBITDA multiple determines the total value of a business relative to its operating profit before depreciation and interest. This calculation allows for an assessment of the real value of assets by neutralizing the impact of tax policy and debt load. By analyzing the business valuation via the EV/EBITDA ratio, an investor can see the market value of the innovations at Molecular Partners (MOLN). For the DARPin biotech platform, this indicator reflects the monetization efficiency of patented protein engineering in the creation of multispecific drugs.

Direct competitors

Geron Corp. - Enterprise Value to EBITDA Ratio|Nanobiotix Group (NBTX) - Company Value to EBITDA|BCYC: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CTMX (cytomx.com)|perspectivetherapeutics.com (CATX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GNLX (Genelux)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oncolytics Biotech, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LSTA|EV/EBITDA Multiple MBRX|EV/EBITDA Multiple galeratx.com (GRTX)|Molecular Templates, Inc. - Enterprise Value to EBITDA Ratio